Applied Biosciences (Applied Biosciences) EBIT per Share : $-0.21 (TTM As of Dec. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Applied Biosciences EBIT per Share?

Applied Biosciences's EBIT per Share for the three months ended in Dec. 2019 was $-0.10. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2019 was $-0.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Applied Biosciences's EBIT per Share or its related term are showing as below:

APPB's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Applied Biosciences's EBIT for the three months ended in Dec. 2019 was $-1.34 Mil.

Applied Biosciences EBIT per Share Historical Data

The historical data trend for Applied Biosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Biosciences EBIT per Share Chart

Applied Biosciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

EBIT per Share

-0.01

-0.16

Applied Biosciences Quarterly Data
	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
EBIT per Share	Get a 7-Day Free Trial															-0.12	-0.01	-0.04	-0.06	-0.10

Applied Biosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Applied Biosciences's EBIT per Share for the fiscal year that ended in Mar. 2018 is calculated as

	EBIT per Share		(A: Mar. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.387	/	15.071
=	-0.16

Applied Biosciences's EBIT per Share for the quarter that ended in Dec. 2019 is calculated as

	EBIT per Share		(Q: Dec. 2019 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.337	/	13.649
=	-0.10

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21

Applied Biosciences (OTCPK:APPB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Applied Biosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Applied Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Biosciences (Applied Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Applied Biosciences Corp (OTCPK:APPB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 Park Avenue, 18th Floor, New York, NY, USA, 10022

Website

https://www.appliedbiocorp.com

Applied Biosciences Corp is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. The company also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to its customers.

Executives

Michael Beaubaire	director	9701 WILSHIRE BLVD. SUITE 1000 BEVERLY HILLS CA 90212
John Robert Brady	10 percent owner	9701 WILSHIRE BLVD., SUITE 1000 BEVERLY HILLS CA 90212
Raymond W. Urbanski	director, officer: Chief Executive Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Scott B Stevens	director	9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Chris Bridges	director, officer: President	9701 WILSHIRE BLVD., SUITE 1000 BEVERLY HILLS CA 90212
John James Southard	officer: Secretary and Treasurer	9701 WILSHIRE BLVD., SUITE 1000 BEVERLY HILLS CA 90212
Sbs Family Trust	10 percent owner	521 RXR PLAZA EAST TOWER ? SUITE 521 UNIONDALE NY 11556